Filing Details
- Accession Number:
- 0000903423-16-001321
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-10-26 17:51:30
- Reporting Period:
- 2016-10-24
- Filing Date:
- 2016-10-26
- Accepted Time:
- 2016-10-26 17:51:30
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1674416 | Crispr Therapeutics Ag | CRSP | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1595117 | Simeon George | C/O S.r. One, Limited 161 Washington Street, Suite 500 Conshohocken PA 19428 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Shares | Acquisiton | 2016-10-24 | 2,942,560 | $0.00 | 2,942,560 | No | 4 | C | Indirect | See explanation of responses |
| Common Shares | Acquisiton | 2016-10-24 | 211,567 | $0.00 | 3,154,127 | No | 4 | C | Indirect | See explanation of responses |
| Common Shares | Acquisiton | 2016-10-24 | 66,500 | $14.00 | 3,220,627 | No | 4 | P | Indirect | See explanation of responses |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See explanation of responses |
| No | 4 | C | Indirect | See explanation of responses |
| No | 4 | P | Indirect | See explanation of responses |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Shares | Series A-3 Preferred Shares | Disposition | 2016-10-24 | 2,942,560 | $0.00 | 2,942,560 | $0.00 |
| Common Shares | Series B Preferred Shares | Disposition | 2016-10-24 | 211,567 | $0.00 | 211,567 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- On October 24, 2016, S.R. One, Limited ("S.R. One") acquired 66,500 common shares of the Issuer ("Common Shares") at a price of $14.00 per share in connection with the Issuer's initial public offering.
- These shares are held of record by S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Simeon J. George (the "Reporting Person") is a Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. The Reporting Person disclaims beneficial ownership of all the shares herein and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his proportionate pecuniary interest therein, if any.
- On October 24, 2016, the Series A-3 Preferred Shares and the Series B Preferred Shares converted automatically into Common Shares on a one-for-one basis, upon closing of the Issuer's initial public offering
- Not applicable.
Billionaire Hedge Funds
